Marco Derhy

We exist to grow DC for the people of our city. Whether your desire is to create exceptional affordable housing or an elegant luxury condo, our aim to to see the District thrive.

Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics​ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory. For more information, visit www.bridgetherapeutics.com.

TerraLux pioneers sustainable, technology-driven living, seamlessly integrating nature, innovation, and human well-being. By blending advanced smart technologies with organic design, we create immersive environments that redefine how people live, work, and connect. Through smart homes, AI-driven experiences, and regenerative design, we empower individuals and communities to embrace a future where luxury, sustainability, and innovation coexist effortlessly. Our solutions are designed to empower businesses, individuals, and communities to thrive in harmony with a rapidly changing world. From intelligent tools to visionary systems, our mission is to turn possibility into meaningful progress.

Advent is a film, television, video game and interactive multimedia company that is connecting powerful storytelling and the latest technology to expand entertainment capabilities beyond the brink of human imagination.

C-Gold Technologies LLC, Dba Great American Bullion, Cheaper Bullion, Private Coins and Bullion

We exist to grow DC for the people of our city. Whether your desire is to create exceptional affordable housing or an elegant luxury condo, our aim to to see the District thrive.

Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics​ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory. For more information, visit www.bridgetherapeutics.com.